Equity Profile

PTGX

Protagonist Therapeutics, Inc.

Health CareBiotechnology$8.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Protagonist Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a critical indicator of profitability and will show how well the company is managing its costs and generating revenue.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

PTGX Q2-2026 Earnings Preview

Context

Company Snapshot

Protagonist Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for serious diseases. Operating in the health care sector, its innovative approach to drug development is significant as it aims to address unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+397.37%

Avg Stock Reaction

-0.19%

Last Quarter Recap

In Q1-2026, Protagonist reported an EPS of $0.05, significantly exceeding expectations. However, revenue details were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Protagonist's upcoming earnings report, especially following a surprising EPS beat last quarter. However, the lack of revenue guidance raises concerns.

Bull Case

If the company continues to show strong EPS performance and provides positive updates on its drug pipeline, it could lead to increased investor confidence and stock appreciation.

Bear Case

On the other hand, if the company fails to provide clarity on revenue or if there are signs of operational challenges, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given the significant surprise last quarter, the EPS figure will be critical in assessing the company's ongoing profitability and operational efficiency.

Will there be any updates on revenue or product pipeline?

Clarity on revenue and the status of drug development will be essential for understanding the company's growth potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Protagonist to deliver strong EPS again, given its recent performance and the lack of revenue guidance.

Supporting Evidence

The options market is pricing a significant move, indicating expectations of volatility that may not align with historical performance.

The recent EPS surprise suggests that the company may be better positioned than analysts anticipate.

Key Risk

If the EPS comes in above $0.05, it could challenge the cautious outlook and shift sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is crucial for validating the company's growth trajectory and addressing investor concerns about revenue.

Bull Confirmed If

An EPS of $0.10 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.00 would indicate ongoing challenges and could lead to a decline in stock price.

Pre-Earnings Positioning

Options Market

Implied Move

±18.21%

Historical Avg

±1.3%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±18.2% while PTGX has averaged ±1.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.0%

Calls (18K)P/C Ratio: 2.50Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Protagonist beats expectations, history suggests the stock could rise by around 1.27%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of about 0.80%, reflecting disappointment and potential concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the status of drug development programs.
2Updates on partnerships or collaborations that could impact revenue.
3Insights into cost management strategies and their effects on profitability.
4Any guidance on future earnings or revenue expectations.
5Management's outlook on market conditions and competitive landscape.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Protagonist Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a critical indicator of profitability and will show how well the company is managing its costs and generating revenue.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

PTGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+397.37%

Avg Stock Reaction

-0.19%

Last Quarter Recap

In Q1-2026, Protagonist reported an EPS of $0.05, significantly exceeding expectations. However, revenue details were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Protagonist's upcoming earnings report, especially following a surprising EPS beat last quarter. However, the lack of revenue guidance raises concerns.

Bull Case

If the company continues to show strong EPS performance and provides positive updates on its drug pipeline, it could lead to increased investor confidence and stock appreciation.

Bear Case

On the other hand, if the company fails to provide clarity on revenue or if there are signs of operational challenges, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given the significant surprise last quarter, the EPS figure will be critical in assessing the company's ongoing profitability and operational efficiency.

Will there be any updates on revenue or product pipeline?

Clarity on revenue and the status of drug development will be essential for understanding the company's growth potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Protagonist to deliver strong EPS again, given its recent performance and the lack of revenue guidance.

Supporting Evidence

The options market is pricing a significant move, indicating expectations of volatility that may not align with historical performance.

The recent EPS surprise suggests that the company may be better positioned than analysts anticipate.

Key Risk

If the EPS comes in above $0.05, it could challenge the cautious outlook and shift sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is crucial for validating the company's growth trajectory and addressing investor concerns about revenue.

Bull Confirmed If

An EPS of $0.10 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.00 would indicate ongoing challenges and could lead to a decline in stock price.

Pre-Earnings Positioning

Options Market

Implied Move

±18.21%

Historical Avg

±1.3%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±18.2% while PTGX has averaged ±1.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.0%

Calls (18K)P/C Ratio: 2.50Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Protagonist beats expectations, history suggests the stock could rise by around 1.27%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of about 0.80%, reflecting disappointment and potential concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the status of drug development programs.
2Updates on partnerships or collaborations that could impact revenue.
3Insights into cost management strategies and their effects on profitability.
4Any guidance on future earnings or revenue expectations.
5Management's outlook on market conditions and competitive landscape.